The instant invention provides for inositol derivatives, analogs, methods of preparation and uses that inhibit oncogenic signaling pathways and genes. In particular, the compounds disclosed selectively inhibit one or two classes and or isoforms of PI3K. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting KRAS by administering the compound to a patient in need of treatment of cancer.

The instant invention provides for inositol derivatives, analogs, methods of preparation and uses that inhibit oncogenic signaling pathways and genes. In particular, the compounds disclosed selectively inhibit one or two classes and or isoforms of PI3K. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting KRAS by administering the compound to a patient in need of treatment of cancer.

[Problem] To provide a composition for external skin use that has anti-inflammatory and antiallergic activity, and is very safe. [Solution] A composition for external skin use for inflammatory diseases contains dihomo-gamma-linolenic acid (DGLA) as the active ingredient thereof. It is preferable for the DGLA to be present as a glyceride, a phospholipid, or an alkyl ester. The amount of DGLA contained in the composition for external use is 0.1-50 wt %.

[Problem] To provide a composition for external skin use that has anti-inflammatory and antiallergic activity, and is very safe. [Solution] A composition for external skin use for inflammatory diseases contains dihomo-gamma-linolenic acid (DGLA) as the active ingredient thereof. It is preferable for the DGLA to be present as a glyceride, a phospholipid, or an alkyl ester. The amount of DGLA contained in the composition for external use is 0.1-50 wt %.

Methods, compositions and kits comprising alpha-adrenergic antagonists, such as phentolamine, for the treatment of glaucoma, ocular hypertension, and/or other ocular disorders, such as non-arteritic anterior ischemic optic neuropathy or keratoconus, are provided. Said methods, compositions and kits may further comprise additional therapeutic agents, including prostaglandin analogues such as latanoprost, beta-adrenergic antagonists, alpha-adrenergic agonists, carbonic anhydrase inhibitors, cholinergic agonists, NMDA receptor antagonist, adenosine receptor antagonists, 5-HT2a receptor agonists, or Rho kinase inhibitors.

Methods, compositions and kits comprising alpha-adrenergic antagonists, such as phentolamine, for the treatment of glaucoma, ocular hypertension, and/or other ocular disorders, such as non-arteritic anterior ischemic optic neuropathy or keratoconus, are provided. Said methods, compositions and kits may further comprise additional therapeutic agents, including prostaglandin analogues such as latanoprost, beta-adrenergic antagonists, alpha-adrenergic agonists, carbonic anhydrase inhibitors, cholinergic agonists, NMDA receptor antagonist, adenosine receptor antagonists, 5-HT2a receptor agonists, or Rho kinase inhibitors.

A reservoir device comprising an active agent formulation contained within a reservoir is described. The reservoir is defined by a biodegradable, permeable polymer membrane having a thickness of at least 45 μm. The membrane allows for diffusion of an active agent of the formulation there through when positioned subcutaneously in a body of a subject.

A reservoir device comprising an active agent formulation contained within a reservoir is described. The reservoir is defined by a biodegradable, permeable polymer membrane having a thickness of at least 45 μm. The membrane allows for diffusion of an active agent of the formulation there through when positioned subcutaneously in a body of a subject.

The present invention relates to a composition comprising, as active ingredients: (1) a biguanide-based compound or a pharmaceutically acceptable salt thereof; (2) 2-deoxy-D-glucose; and (3) inositol hexaphosphate or a pharmaceutically acceptable salt thereof, inositol, or a mixture thereof. The composition according to the present invention exhibits a synergistic anticancer effect by appropriately combining specific drugs having a problem that needs to be used in a large amount, thereby making it possible to kill cancer cells in a small amount and effectively treat the cancer. Furthermore, the composition of the present invention may kill only cancer cells without side effects by exhibiting a specific toxic effect on cancer cells without showing toxicity on normal cells and thus be usefully used as an anticancer agent and for preventing or improving cancer.

The present invention relates to a composition comprising, as active ingredients: (1) a biguanide-based compound or a pharmaceutically acceptable salt thereof; (2) 2-deoxy-D-glucose; and (3) inositol hexaphosphate or a pharmaceutically acceptable salt thereof, inositol, or a mixture thereof. The composition according to the present invention exhibits a synergistic anticancer effect by appropriately combining specific drugs having a problem that needs to be used in a large amount, thereby making it possible to kill cancer cells in a small amount and effectively treat the cancer. Furthermore, the composition of the present invention may kill only cancer cells without side effects by exhibiting a specific toxic effect on cancer cells without showing toxicity on normal cells and thus be usefully used as an anticancer agent and for preventing or improving cancer.